ZA200307102B - The use of enmantiomeric pure escitalopram. - Google Patents

The use of enmantiomeric pure escitalopram.

Info

Publication number
ZA200307102B
ZA200307102B ZA200307102A ZA200307102A ZA200307102B ZA 200307102 B ZA200307102 B ZA 200307102B ZA 200307102 A ZA200307102 A ZA 200307102A ZA 200307102 A ZA200307102 A ZA 200307102A ZA 200307102 B ZA200307102 B ZA 200307102B
Authority
ZA
South Africa
Prior art keywords
enmantiomeric
pure escitalopram
escitalopram
pure
enmantiomeric pure
Prior art date
Application number
ZA200307102A
Other languages
English (en)
Inventor
Connie Sanchez
Jesper Lyng Jensen
Arne Mork
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of ZA200307102B publication Critical patent/ZA200307102B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200307102A 2001-05-01 2003-09-11 The use of enmantiomeric pure escitalopram. ZA200307102B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200100684 2001-05-01

Publications (1)

Publication Number Publication Date
ZA200307102B true ZA200307102B (en) 2004-09-13

Family

ID=8160464

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200307102A ZA200307102B (en) 2001-05-01 2003-09-11 The use of enmantiomeric pure escitalopram.

Country Status (25)

Country Link
US (7) US20040198809A1 (de)
EP (1) EP1385503A1 (de)
JP (1) JP2004527551A (de)
KR (2) KR20040030609A (de)
CN (1) CN1509169A (de)
AR (1) AR033308A1 (de)
AT (1) AT10974U1 (de)
BG (1) BG108379A (de)
BR (1) BR0208283A (de)
CA (1) CA2445843A1 (de)
CZ (1) CZ20033267A3 (de)
EA (1) EA200301195A1 (de)
HR (1) HRP20030744A2 (de)
HU (1) HUP0400054A3 (de)
IL (1) IL158031A0 (de)
IS (1) IS6954A (de)
ME (1) MEP5908A (de)
MX (1) MXPA03008777A (de)
NO (1) NO20034538L (de)
PL (1) PL367480A1 (de)
SK (1) SK14612003A3 (de)
UA (1) UA82828C2 (de)
WO (1) WO2002087566A1 (de)
YU (1) YU85303A (de)
ZA (1) ZA200307102B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
JP2004527551A (ja) * 2001-05-01 2004-09-09 ハー・ルンドベック・アクチエゼルスカベット エナンチオ純粋なエスシタロプラムの使用方法
PL378275A1 (pl) * 2002-12-23 2006-03-20 H. Lundbeck A/S Bromowodorek escitalopramu i sposób jego wytwarzania
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
EA200601641A1 (ru) * 2004-03-05 2006-12-29 Х. Лундбекк А/С Кристаллическая композиция, содержащая оксалат эсциталопрама
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
WO2007048080A2 (en) * 2005-10-14 2007-04-26 Forest Laboratories, Inc. Stable pharmaceutical formulations containing escitalopram and bupropion
US7569605B2 (en) 2005-10-14 2009-08-04 Forest Laboratories Holdings Limited Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
EP2086509A1 (de) * 2006-10-20 2009-08-12 Ratiopharm GmbH Escitalopram und dieses enthaltende feste pharmazeutische zusammensetzung
US20100003313A1 (en) * 2006-10-27 2010-01-07 Hisamitsu Pharmaceutical Co.,Inc. Adhesive skin patch
EP2017271A1 (de) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Verfahren zur Herstellung von Escitalopram
KR101612563B1 (ko) * 2007-08-03 2016-04-14 리히터 게데온 닐트. 도파민 수용체 리간드를 함유하는 약학적 조성물 및 도파민 수용체 리간드를 사용한 치료 방법
CN101983193B (zh) * 2008-01-31 2014-03-12 武田药品工业株式会社 注意缺陷/多动障碍的预防或治疗剂
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
WO2010098230A1 (ja) * 2009-02-27 2010-09-02 久光製薬株式会社 経皮投与製剤
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
WO2016180879A1 (en) * 2015-05-13 2016-11-17 A. Carlsson Research Ab Treatment of debilitating fatigue

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143702A (de) * 1965-03-18
US4079135A (en) * 1973-12-13 1978-03-14 Imperial Chemical Industries Limited Morpholine derivatives as antidepressants
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (de) * 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
CA2291072C (en) * 1997-11-11 2002-08-20 H. Lundbeck A/S Method for the preparation of citalopram
US6353008B1 (en) * 1998-06-30 2002-03-05 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
DK1123284T3 (da) * 1998-10-20 2003-04-28 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
HU227473B1 (en) * 1999-04-14 2011-07-28 Lundbeck & Co As H Method for preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
WO2001080845A2 (en) * 2000-04-24 2001-11-01 Aryx Therapeutics (2-aminoethyl) oxime derivatives for the treatment of depression
JP2004527551A (ja) * 2001-05-01 2004-09-09 ハー・ルンドベック・アクチエゼルスカベット エナンチオ純粋なエスシタロプラムの使用方法

Also Published As

Publication number Publication date
KR20100012089A (ko) 2010-02-05
US20040192766A1 (en) 2004-09-30
AR033308A1 (es) 2003-12-10
US20040192765A1 (en) 2004-09-30
BG108379A (bg) 2004-11-30
US20040198810A1 (en) 2004-10-07
CN1509169A (zh) 2004-06-30
WO2002087566A1 (en) 2002-11-07
YU85303A (sh) 2006-05-25
AT10974U1 (de) 2010-02-15
US20080004338A1 (en) 2008-01-03
US20040198809A1 (en) 2004-10-07
UA82828C2 (en) 2008-05-26
CA2445843A1 (en) 2002-11-07
IL158031A0 (en) 2004-03-28
IS6954A (is) 2003-09-15
US20040198811A1 (en) 2004-10-07
KR20040030609A (ko) 2004-04-09
CZ20033267A3 (en) 2004-06-16
US20040192764A1 (en) 2004-09-30
EA200301195A1 (ru) 2004-04-29
MEP5908A (xx) 2010-02-10
EP1385503A1 (de) 2004-02-04
HUP0400054A2 (hu) 2004-04-28
HRP20030744A2 (en) 2005-06-30
NO20034538D0 (no) 2003-10-09
JP2004527551A (ja) 2004-09-09
NO20034538L (no) 2003-10-09
SK14612003A3 (sk) 2004-04-06
BR0208283A (pt) 2004-03-09
PL367480A1 (en) 2005-02-21
HUP0400054A3 (en) 2007-03-28
MXPA03008777A (es) 2004-02-12

Similar Documents

Publication Publication Date Title
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
ZA200307102B (en) The use of enmantiomeric pure escitalopram.
HK1078266A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
ZA200208561B (en) Hydraulischer druckverstarker.
MXPA03007834A (es) Uso de agonistas inversos de gabaa, en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de transtornos cognitivos.
MXPA01009037A (es) I-bet.
MXPA03005286A (es) METODO Y APARATO PARA SUPERVISAR PULSACION DE INSTALACION DE ORDEnA.
MXPA03008139A (es) Fluoralcoxifenilsulfonilureas sustituidas.
HK1066022A1 (en) Use of 1,1,1,3,3-pentafluorobutan
MXPA03007888A (es) Compuestos para tratamiento y prevencion de ulcera gastrica inducida por medicamentos.
HK1059781A1 (en) New phenylpiperazines.
GB0112267D0 (en) The pagekeeper
GB0124935D0 (en) The safetycom
ZA200306611B (en) New use.
EG23305A (en) Preparation of 1,2-dicloroethane.
ZA200300620B (en) Provision of video-on-demand.
GB0105446D0 (en) S.s.h.p.s
GB0112516D0 (en) V.i.s.c
ZA200108074B (en) Structure.
AP2001000098S (en) Marimbira.
MXPA01005709A (es) Panel-cimbra.
MXPA01005710A (es) Losa-cimbra.
GB0116210D0 (en) P.c.o
GB0118494D0 (en) P.c.o.
ZA200203782B (en) Apension scheme.